

A COMPARISON OF DIFFERENT MODELS OF THERAPY WITH AZITHROMYCIN (AZIMED) OF PATIENTS WITH MILD COMMUNITY-ACQUIRED PNEUMONIA

*Yu. M. Mostovoy, A. V. Demchuk,
B. S. Demchuk*

Summary

Oral formulations of microlides belong to medicines of choice in outpatients with mild community-acquired pneumonia. We conducted a comparative efficacy and safety study of 3 (500 mg QD) and 5 (500 mg QD on the first day and 250 mg QD on 2–5th days) doses regimens of azithromycin (Azimed) in 40 patients with mild community-acquired pneumonia aged 18–60 years. Based on the results of the study we proved high efficacy of both regimens of treatment with azithromycin (95 % in 3 doses and 100 % in 5 doses regimen ($p < 0,1$)). Considering its efficacy and safety azithromycin could be recommended as antibiotic of choice in less than 60 years old patients with mild community-acquired pneumonia.